As the first biologic targeting IL-17 approved for the management of psoriasis, secukinumab has been proven to provide safe, rapid, and sustained improvements in patients with plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis. This evidence concerns the gene IL17A and psoriasis vulgaris.